Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


The Ups and Downs Of US Drug Pricing Policy

Executive Summary

If 2017 was the year of talk (tweets) on prescription drug pricing policy, 2018 is shaping up to be the year of action.


Related Content

UnitedHealthcare Will Share The Savings: Point-Of-Sale Rebates Coming In 2019
The Budget Blindside: Did Pharma Fight The Wrong Battle?
Fight Brewing In Congress Over Part D Coverage Gap Discounts
At Cross-Purposes? How Trump Budget's Part D Gap Discount Policy Aligns With New Law
HHS Secretary Azar Likely To Advance Medicare Drug Pricing Policies
Rebate Pass-Through Would Lower, Not Raise, Medicare Spending – PhRMA
340B Provider Reforms Gaining Momentum In Congress
Breaking 340B: What Happens After Medicare Payment Cut?
OMB's Grogan Talks Drug Pricing And Taking On 'Sacred Cows'
Trump Throws Pharma A Curve Ball On The Third Day Of J.P. Morgan


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts